[go: up one dir, main page]

DK442788D0 - Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser - Google Patents

Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser

Info

Publication number
DK442788D0
DK442788D0 DK442788A DK442788A DK442788D0 DK 442788 D0 DK442788 D0 DK 442788D0 DK 442788 A DK442788 A DK 442788A DK 442788 A DK442788 A DK 442788A DK 442788 D0 DK442788 D0 DK 442788D0
Authority
DK
Denmark
Prior art keywords
ige
preparation
treatment
mediated disorders
disorders
Prior art date
Application number
DK442788A
Other languages
English (en)
Other versions
DK442788A (da
Inventor
Gary Scott Hahn
Original Assignee
Gary Scott Hahn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gary Scott Hahn filed Critical Gary Scott Hahn
Publication of DK442788D0 publication Critical patent/DK442788D0/da
Publication of DK442788A publication Critical patent/DK442788A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DK442788A 1986-12-09 1988-08-08 Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser DK442788A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/939,927 US4816449A (en) 1984-08-09 1986-12-09 Immunotherapeutic anti-inflammatory peptide agents
PCT/US1987/003223 WO1988004178A1 (en) 1986-12-09 1987-12-09 METHODS AND PEPTIDES FOR THE TREATMENT OF NON-IgE-MEDIATED DISEASES

Publications (2)

Publication Number Publication Date
DK442788D0 true DK442788D0 (da) 1988-08-08
DK442788A DK442788A (da) 1988-10-07

Family

ID=25473943

Family Applications (2)

Application Number Title Priority Date Filing Date
DK442688A DK442688A (da) 1986-12-09 1988-08-08 Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
DK442788A DK442788A (da) 1986-12-09 1988-08-08 Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK442688A DK442688A (da) 1986-12-09 1988-08-08 Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser

Country Status (8)

Country Link
US (1) US4816449A (da)
EP (1) EP0335901B1 (da)
JP (2) JPH02501573A (da)
AT (1) ATE126441T1 (da)
AU (2) AU1049788A (da)
DE (1) DE3751470T2 (da)
DK (2) DK442688A (da)
WO (2) WO1988004177A1 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061692A (en) * 1984-08-09 1991-10-29 Immunetech Pharmaceuticals Methods and compositions for the treatment of non-IgE-mediated diseases
US5468730A (en) * 1984-08-09 1995-11-21 Dura Pharmaceuticals, Inc. Methods for the treatment of non-IgE-mediated diseases
GB8905606D0 (en) * 1989-03-11 1989-04-26 Scras Peptides
US5252464A (en) * 1989-03-14 1993-10-12 Carlsberg Biotechnology Ltd. A/S Process for producing pentapeptides and intermediates for use in the synthesis
DK122489D0 (da) * 1989-03-14 1989-03-14 Carlsberg Biotechnology Ltd Fremgangsmaade til fremstilling af pentapeptider samt mellemprodukter til brug ved fremstillingen
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
US5028593A (en) * 1989-08-15 1991-07-02 Board Of Regents, The University Of Texas System Tuftsin analogs
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5223487A (en) * 1989-09-30 1993-06-29 Hitachi Chemical Co., Ltd. Peptides as antiallergic agents
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US5681555A (en) * 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
DK0510912T3 (da) * 1991-04-24 1998-02-09 Morinaga Milk Industry Co Ltd Antimikrobielt peptid og antimikrobielt middel
GB9211668D0 (en) * 1992-06-02 1992-07-15 Nycomed Bioreg As Peptide compounds
US6177405B1 (en) * 1992-07-22 2001-01-23 Kenji Nishioka Cyclic analogs of tuftsin
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5705481A (en) * 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
IL108031A0 (en) * 1992-12-22 1994-04-12 Procter & Gamble Difluoro pentapeptide derivatives and pharmaceutical compositions containing them
ATE276272T1 (de) * 1993-06-18 2004-10-15 Curative Tech Inc Entzündungshemmende peptide
GB9320897D0 (en) * 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
GB9509957D0 (en) * 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
AU749471B2 (en) 1998-01-20 2002-06-27 Myriad Genetics, Inc. MMSC1 - an MMAC1 interacting protein
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
ATE430199T1 (de) * 1998-01-31 2009-05-15 Univ Arkansas Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
US6767890B1 (en) * 1998-11-18 2004-07-27 Coastside Bio Resources Peptides having anti-cancer and anti-inflammatory activity
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
WO2001066136A2 (en) * 2000-04-06 2001-09-13 Panacea Pharmaceuticals, Llc. Microbial delivery system
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6908899B2 (en) * 2001-08-17 2005-06-21 U.S. Dept. Of Veterans Affairs Pro-inflammatory fibrinopeptide
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
EP1421108A2 (en) 2001-08-24 2004-05-26 Micrologix Biotech, Inc. Antimicrobial and anti-inflammatory peptides
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
ATE490969T1 (de) * 2001-08-30 2010-12-15 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
EP1545595B1 (en) * 2002-08-30 2010-07-07 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CA2506839A1 (en) * 2002-11-20 2004-06-03 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AU2004238285A1 (en) * 2003-05-07 2004-11-25 Dmi Biosciences, Inc Oral care methods and products
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
AU2004275821A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize N-acyl-L-aspartic acid
EP1568707A1 (en) * 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
ES2371495T3 (es) * 2006-07-24 2012-01-03 Biorexis Pharmaceutical Corporation Proteínas de fusión de exendina.
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
ES2875853T3 (es) 2013-03-15 2021-11-11 Univ Texas Método de tratar fibrosis
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
JP7496826B2 (ja) 2018-09-10 2024-06-07 ラング セラピューティクス，エルエルシー Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
EP3946643A1 (en) 2019-03-26 2022-02-09 International Flavors & Fragrances Inc. Use of polylysine dendrimers in the prevention and management of acne-prone skin and acneic skin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065808A (en) * 1975-01-25 1977-12-27 U.S. Philips Corporation Network computer system
DE2602443A1 (de) * 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4392997A (en) * 1981-07-06 1983-07-12 Northwestern University Antigenic peptide compounds
US4814973A (en) * 1983-05-31 1989-03-21 Hillis W Daniel Parallel processor
US4683292A (en) * 1983-08-12 1987-07-28 Immunetech, Inc. Immunotherapeutic polypeptide agents which bind to lymphocyte immunoglobulin FC receptors
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
JPH07120275B2 (ja) * 1983-12-28 1995-12-20 株式会社日立製作所 シミューションプログラム生成方法
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
JPH02501573A (ja) 1990-05-31
EP0335901A4 (en) 1990-11-28
DE3751470D1 (de) 1995-09-21
DK442688D0 (da) 1988-08-08
DK442688A (da) 1988-10-07
ATE126441T1 (de) 1995-09-15
AU612341B2 (en) 1991-07-11
WO1988004177A1 (en) 1988-06-16
DE3751470T2 (de) 1996-04-04
AU1056788A (en) 1988-06-30
US4816449A (en) 1989-03-28
DK442788A (da) 1988-10-07
AU1049788A (en) 1988-06-30
EP0335901A1 (en) 1989-10-11
EP0335901B1 (en) 1995-08-16
WO1988004178A1 (en) 1988-06-16
JPH02501066A (ja) 1990-04-12

Similar Documents

Publication Publication Date Title
DK442688A (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
NO911694L (no) Mikroemulsjonsblanding til haarbehandling, fremgangsmaate for fremstilling og anvendelse derav.
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DK467487A (da) Polypeptid, anvendeligt til lindring, behandling og diagnosticering af autoimmunitetssygdomme, isaer arthritis
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DK526689D0 (da) Fremgangsmaade til behandling og forebyggelse af pneumocystis carinii pheumonia og andre sygdomme, og forbindelser og formuleringer til anvendelse ved denne fremgangsmaade
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
PT99265A (pt) Processo para a preparacao de composicoes farmaceuticas contendo interferon humano e metodo de tratamento de doencas proliferativas celulares
DK67683D0 (da) Fremgangsmade til fremstilling af 2,3-diaryl-5-halogen-thio-phener
DE3871010D1 (de) Behandlung von unfruchtbarkeit.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
NO871137L (no) Ikke-betennelsesfremkallende hyaluronsyrefraksjon og fremgangsmaate for fremstilling av denne.
DK585984A (da) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan og salte deraf til anvendelse ved bekaempelse af sygdomme samt fremgangsmaade til fremstilling af saadanne nonanderivater
ATE71307T1 (de) Verfahren zur behandlung von kontaktlinsen.
DK320081A (da) Fremgangsmaade til fremstilling af thiazolyl-2-oxamidsyrederivater
DK670588D0 (da) Farmaceutisk praeparat til behandling af phlebektasi og fremgangsmaade til fremstilling af praeparatet
DK72088D0 (da) Oximethere af 2,6-dioxabicyclo(3.3.0)octanoner og farmaceutiske praeparater til behandling af hjerte- og blodkredsloebssygdomme
NO900044L (no) Hemorroidale, andre blandinger og metoder for behandling.
DE3680140D1 (de) Behandlung von parasiterkrankungen.
DK165475C (da) Fremgangsmaade og anlaeg til behandling eller undersoegelse af slagtekroppe
DK169087D0 (da) Praeparat til prophylakse og behandling af svinesygdomme
IS2729A7 (is) Hreinsaðar antineoplaston hlutar og aðferð til meðferðar neoplastic-veiki

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment